At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Liquid 13-Cis Retinoic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability and Comparative Pharmacokinetics of 13-CRA Oral Liquid and Extracted Capsule Formulations: a Randomised, Open Label, Multi-dose, Cross-over Clinical Trial in Patients Requiring Treatment Cycles of 13-CRA.
In Brief
A Phase 2 clinical trial evaluating Liquid 13-Cis Retinoic Acid and Extracted capsules 13-CRA for Neuroblastoma. Completed, enrolled 20 participants across 10 sites.
Detailed Summary
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - \< 21 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartApr 2018
Primary CompletionSep 2019
TodayJul 2026
First PostedSep 25, 2017
Enrollment StartApr 17, 2018
Primary CompletionSep 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.8 years ago
Interventions
Liquid 13-Cis Retinoic Aciddrug
Liquid 13-Cis Retinoic Acid
Extracted capsules 13-CRAdrug
Extracted capsules 13-CRA